



Press Release

January 31, 2018

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

**Strides Shasun receives USFDA Approval for Nystatin and
Triamcinolone Acetonide Ointment**

First topical approval from flagship plant in Bangalore

Bangalore, January 31, 2018, Strides Shasun Limited today announced that it's wholly owned subsidiary Strides Pharma Global Pte. Limited has received approval for ***Nystatin and Triamcinolone Acetonide Ointment USP, 0.1%*** from the United States Food & Drug Administration (USFDA). This is the first topical approval received from the new semi solids block at the flagship plant in Bangalore. The topical product line is an important new addition to Strides' portfolio of oral solid dosage products and the Bangalore manufacturing plant supports several current and future topical submissions for the US Market. The product received approval within ten months under the GDUFA regime.

According to IMS data, the US market for ***Nystatin and Triamcinolone Acetonide Ointment USP, 0.1%*** is approximately USD 18 Million. The product will be marketed by Strides Pharma Inc. in the US Market.

About *Nystatin and Triamcinolone Acetonide Ointment*

Nystatin and Triamcinolone Acetonide Ointment is used in treatment of fungal skin infections. The product contains nystatin, an anti-fungal drug that works by stopping the growth of fungus. It also contains triamcinolone, an anti-inflammatory corticosteroid that works by reducing swelling, itching, and redness.

About Strides Shasun

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has three business verticals, viz., Regulated Markets, Emerging Markets and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<p><u>Strides</u></p> <p>Shashank Sinha, Managing Director +91 80 6784 0335</p> <p><u>Investors:</u></p> <p>Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791</p> <p>Strides Shasun Limited CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector – 17, Vashi, Navi Mumbai – 400 703 Email: investors@stridesshasun.com</p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com</p> <p>K Priya: +91 9535425418 priya@fortunapr.com</p>
---	--